PatientID: HIVDR-1736-23

Sebuttemba 27, 2023

Color Code

HR: High-Level Resistance

LR: Low-Level Resistance

IR: Intermediate Resistance

S: Susceptible

DRUG.CLASS	DRUG	RESISTANCE.PROFILE	DRMS.above.20.percent.prevalence
PI	ATV	S	
	DRV	\mathbf{S}	
	FPV	\mathbf{S}	
	IDV	\mathbf{S}	
	LPV	${f S}$	
	NFV	${f S}$	
	SQV	${f S}$	
	TPV	${f S}$	
NRTI	ABC	LR	
	AZT	${f S}$	
	D4T	${f S}$	
	DDI	PLR	M184V
	FTC	$_{ m HR}$	
	LMV	$_{ m HR}$	
	TDF	${f S}$	
NNRTI	DOR	IR	
	EFV	$_{ m HR}$	
	ETR	PLR	P225H;K103N;E138A
	NVP	$_{ m HR}$	
	RPV	LR	

Appendix

Drug abbreviations in full

DRUG.CLASS	ABBREVIATION	DRUG.NAME
	ATV	Atazanavir
	DRV	Darunavir
	FPV	Fosamprenavir
PI	IDV	Indinavir
11	LPV	Lopinavir
	NFV	Nelfinavir
	SQV	Saquinavir
	TPV	Tipranavir
	ABC	Abacavir
	AZT	Azidothymidine
	DFT	Stavudine
NRTI	DDI	Didanosine
	FTC	Emtricitabine
	LMV	Lamivudine
	TDF	Tenofovir
	DOR	Doravirine
	EFV	Efavirenz
NNRTI	ETR	Etravirine
	NVP	Nevirapine
	RPV	Rilpivirine
	BIC	Bictegravir
	CAB	Cabotegravir
INSTI	DTG	Dolutegravir
	EVG	Elvitegravir
	RAL	Raltegravir

Comments

DRUG.CLASS	COMMENTS
PI	
NRTI	M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate
	resistance to ABC (3-fold reduced susceptibility). M184V/I are not contraindications to
	continued treatment with 3TC or FTC because they increase susceptibility to AZT and
	TDF and are associated with clinically significant reductions in HIV-1 replication.
	E138A is a common polymorphic accessory mutation weakly selected in persons receiving
	ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. Its effect on ETR- and
	RPV-containing regimens is likely to be minimal.
	K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV
NNRTI	susceptibility. It is the most commonly transmitted DRM.
	P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination
	with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and
	DOR susceptibility.
INSTI	